X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Aclipse gains worldwide rights to develop CKD’s M107 (lobeglitazone), an oral, small molecule, for gastroparesis and additional indications.
Lead Product(s): Lobeglitazone
Therapeutic Area: Gastroenterology Product Name: M107
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Chong Kun Dang Pharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 14, 2023
Details:
Funding supports aclipse therapeutics’ and sheffield institute of translational neuroscience’s development of M102 in amyotrophic lateral sclerosis. M102 is Aclipse’s drug candidate for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): M102
Therapeutic Area: Neurology Product Name: M102
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medical Research Council (U.K)
Deal Size: $2.2 million Upfront Cash: Undisclosed
Deal Type: Funding January 26, 2021
Details:
The grant will support the translational development of M102, a drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease.
Lead Product(s): M102
Therapeutic Area: Neurology Product Name: M102
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: FightMND
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Funding September 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
